PD-1/PD-L1
Os inibidores de PD-1/PD-L1 são inibidores de checkpoints imunológicos que bloqueiam a interação entre a proteína de morte celular programada 1 (PD-1) nas células T e seu ligante PD-L1 nas células cancerígenas. Essa interação normalmente suprime a resposta imunológica e permite que as células cancerígenas evitem a detecção imunológica. Ao inibir PD-1/PD-L1, esses inibidores aumentam a capacidade do sistema imunológico de reconhecer e destruir células cancerígenas, induzindo apoptose e regressão tumoral. Os inibidores de PD-1/PD-L1 são fundamentais na pesquisa em imunoterapia e no tratamento do câncer. Na CymitQuimica, oferecemos uma gama de inibidores de PD-1/PD-L1 de alta qualidade para apoiar sua pesquisa em imunooncologia, apoptose e terapia do câncer.
Foram encontrados 182 produtos para "PD-1/PD-L1".
Filtrar por
Percentagem de pureza
0
100
|
0
|
50
|
90
|
95
|
100
- Preços em ordem crescente
- Preços em ordem decrescente
- Menor grau de pureza
- Maior grau de pureza
- Estimativa de entrega mais rápida
Penpulimab
CAS:Penpulimab is a monoclonal antibody targeting PD-1 with antitumor activity, used in studies of pancreatic cancer.Pureza:96.8% (SEC-HPLC) - 96.8% (SEC-HPLC)Cor e Forma:Transparent LiquidPeso molecular:145.14 kDa (Predicted)Sintilimab
CAS:Sintilimab (IBI308), an IgG4 monoclonal antibody, blocks PD-1, enhancing T-cell anti-tumor response; treats Hodgkin's, lung, and esophageal cancers.Pureza:> 95% - >95.0% (SDS-PAGE); 95.0% (SEC-HPLC)Cor e Forma:LiquidPeso molecular:143.78 kDa (Predicted)Zimberelimab
CAS:Zimberelimab (GLS-010) is a humanized antibody targeting PD-1, with anticancer activity.Pureza:95%Cor e Forma:Transparent LiquidPeso molecular:146.54 kDa (Predicted)AUNP-12 acetate
AUNP-12 acetate is a polypeptide inhibitor of PD-1 that is equivalent to PD-1 and PD-2 in inhibiting lymphocyte proliferation and effector fuction, in additionFórmula:C144H230N40O50Pureza:95.07% - 99.29%Cor e Forma:White SolidPeso molecular:3321.61Durvalumab
CAS:Durvalumab is a humanized antibody for cancer, inhibiting PD-L1/PD-1 and CD80 interactions at very low concentrations.Pureza:97.2% (SDS-PAGE); 95.3% (SEC-HPLC) - 97.7% (SDS-PAGE); 99.59% (SEC-HPLC)Cor e Forma:Transparent LiquidPeso molecular:146.03 kDa (Predicted)BMS-1001 hydrochloride
CAS:BMS-1001 hydrochloride is an orally active inhibitor of human PD-1/PD-L1 immune checkpoint with low-toxicity in cells.BMS-1001 alleviates the inhibitory effectFórmula:C35H35ClN2O7Pureza:97.36%Cor e Forma:SolidPeso molecular:631.115Budigalimab
CAS:Budigalimab (ABBV 181) is a humanized monoclonal antibody targeting PD-1 with potential antitumor activity.Pureza:97% (SDS-PAGE); 98.8% (SEC-HPLC) - 97% (SDS-PAGE); 98.8% (SEC-HPLC)Cor e Forma:Transparent LiquidPeso molecular:145.72 kDa (Predicted)Dostarlimab
CAS:Dostarlimab (TSR-042) is an immune checkpoint inhibitor targeting PD-1, blocking its interaction with its ligands PD-L1 and PD-L2.Pureza:>95%Cor e Forma:Transparent LiquidPeso molecular:144.18 kDa (Predicted)Tislelizumab
CAS:Tislelizumab, a PD-1 receptor monoclonal antibody, reduces Fcγ interaction and T cell clearance in advanced squamous NSCLC research.Pureza:95.07%Cor e Forma:Transparent LiquidPeso molecular:145 kDa (Predicted)Ezabenlimab
CAS:Ezabenlimab (BI-754091) is an anti-PD-1 mAb, Kd 6 nM, blocks PD-1/PD-Ls, boosts T-cell IFN-γ, inhibits tumors in vivo.Pureza:99.1% (SDS-PAGE); 96.9% (SEC-HPLC) - 99.1% (SDS-PAGE); 96.9% (SEC-HPLC)Cor e Forma:Transparent LiquidPeso molecular:145.21 kDa (Predicted)Spartalizumab
CAS:"Spartalizumab (PDR001), a humanized IgG4 monoclonal antibody, targets PD-1 to inhibit PD-L1/L2 interactions, useful in ATC research."Pureza:SDS-PAGE:95.2%;SEC-HPLC:96.3%Cor e Forma:Transparent LiquidPeso molecular:145.74 kDa (Predicted)Garivulimab
CAS:Garivulimab (BGB-A333) is a humanized mAb targeting PD-L1 that enhances T-cell anti-tumor activity by blocking the PD-1/PD-L1 pathway.Pureza:95%Cor e Forma:Transparent LiquidTPP-1 TFA
TPP-1 TFA is a high-affinity PD-L1 inhibitor (KD=95nM) that boosts T-cell function to curb tumor growth.Fórmula:C109H151F3N34O34S2Cor e Forma:SolidPeso molecular:2602.69Eciskafusp alfa
CAS:Eciskafusp alfa, a cis-targeted IL2v immunocytokine, acts on programmed cell death 1 (PDCD1, commonly known as PD-1), preferentially targeting antigen-specificPureza:98%Cor e Forma:SolidSotiburafusp alfa
CAS:Sotiburafusp alfa is a humanized bispecific fusion protein comprising a VEGFR-1 extracellular domain fragment (129-228, 1-100 in the current sequence) connectedPureza:98%Cor e Forma:SolidPD-1/PD-L1-IN-52
PD-1/PD-L1-IN-52 (Compound Ⅲ-5) is an orally active inhibitor of PD-1/PD-L1 interaction, exhibiting an IC50 of 109.9 nM. It demonstrates antitumor activity in a C57BL/6 mouse model of MC38 colon carcinoma cells expressing human PD-1, achieving a tumor growth inhibition (TGI) rate of 49.6%.Cor e Forma:Odour SolidPD-1/PD-L1-IN-9
CAS:PD-1/PD-L1-IN-9, with an IC50 of 3.8 nM, is a potent and orally active inhibitor of the PD-1/PD-L1 interaction.Fórmula:C22H24N2O2Pureza:99.92%Cor e Forma:SolidPeso molecular:348.4382PD-1/PD-L1-IN-48
PD-1/PD-L1-IN-48 (compound HD10) is an effective inhibitor of the PD-1/PD-L1 interaction, exhibiting an IC50 of 3.1 nM. It plays a vital role in cancer research.Cor e Forma:Odour SolidMS1-96
MS1-96 is an orally active PD-L1 (programmed death-ligand 1) degrader. It effectively reduces PD-L1 protein expression levels in various colorectal cancer (CRC) cell lines. The compound loses its ability to induce PD-L1 degradation upon HIP1R knockdown. MS1-96 binds directly to PD-L1 (KD= 2.58 μM) and enhances the interaction between HIP1R and PD-L1, altering PD-L1's intracellular transport in clathrin-coated vesicles. Additionally, MS1-96 induces abnormal N-glycosylation of PD-L1, leading to protein instability and accelerated lysosome-mediated degradation. MS1-96 is applicable for colorectal cancer research.HLX43
HLX43 is an ADC targeting PD-L1 with DAR=8 and a cleavable linker that releases C24, possessing both immune blockade and bystander killing effects.Pureza:95% - 98.30% (SEC-HPLC)Peso molecular:153.06 kDa (Predicted)
